A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).

Trial Details

NCT ID
NCT06084936
Phase
PHASE3
Sponsor
Hoffmann-La Roche
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Obinutuzumab
  • Glofitamab
  • Rituximab
  • Bendamustine
  • Lenalidomide
  • Tocilizumab
Locations (sample)
  • Berkeley, California, United States|37.87159,-122.27275
  • Duarte, California, United States|34.13945,-117.97729
  • Los Angeles, California, United States|34.05223,-118.24368
  • Santa Monica, California, United States|34.01949,-118.49138
  • New Haven, Connecticut, United States|41.30815,-72.92816

Key Eligibility Criteria

  • Life expectancy at least 12 weeks
  • Histologically-confirmed MCL, with documentation of either overexpression of cyclin D1 or the presence of t(11:14) within 12 months of study entry
  • Relapsed (disease progression after the last treatment regimen) or refractory (failure to achieve a partial or complete response from the last trea…
  • At least 1 line of prior systemic therapy including a BTK inhibitor and additional systemic therapy option

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →